Our study aimed to determine whether the consideration of socio-demographic features improves the prediction of Alzheimer’s dementia (AD) at 5 years when using the Free and Cued Selective Reminding Test (FCSRT...
Plasma β-amyloid (Aβ) is a potential candidate for an Alzheimer’s disease (AD) biomarker because blood is an easily accessible bio-fluid, which can be collected routinely, and Aβ is one of the major hallmarks ...
Authors: Jong-Chan Park, Sun-Ho Han, Hyun Jin Cho, Min Soo Byun, Dahyun Yi, Young Min Choe, Seokjo Kang, Eun Sun Jung, Su Jin Won, Eun Hye Kim, Yu Kyeong Kim, Dong Young Lee and Inhee Mook-Jung
Cortical and subcortical cognitive impairments have been found in dementia with Lewy bodies (DLB). Roughly, they comprise visuoconstructive and executive dysfunction, whereas memory would remain relatively spa...
Authors: Jennifer Kemp, Nathalie Philippi, Clélie Phillipps, Catherine Demuynck, Timothée Albasser, Catherine Martin-Hunyadi, Catherine Schmidt-Mutter, Benjamin Cretin and Frédéric Blanc
Accurate and timely diagnosis of Alzheimer’s disease (AD) is important for prompt initiation of treatment in patients with AD and to avoid inappropriate treatment of patients with false-positive diagnoses.
Authors: Spencer A. W. Lee, Luciano A. Sposato, Vladimir Hachinski and Lauren E. Cipriano
Alzheimer’s disease (AD) is a neurodegenerative disorder, primarily affecting memory. That disorder is thought to be a consequence of neuronal network disturbances and synapse loss. Decline in cognitive functi...
Authors: Raphael Hesse, Ludwig Lausser, Pauline Gummert, Florian Schmid, Anke Wahler, Cathrin Schnack, Katja S. Kroker, Markus Otto, Hayrettin Tumani, Hans A. Kestler, Holger Rosenbrock and Christine A. F. von Arnim
There is little information on the application and impact of revised criteria for diagnosing dementia and mild cognitive impairment (MCI), now termed major and mild neurocognitive disorders (NCDs) in the DSM-5...
Authors: Ranmalee Eramudugolla, Moyra E. Mortby, Perminder Sachdev, Chantal Meslin, Rajeev Kumar and Kaarin J. Anstey
The number of people living with dementia is expected to exceed 130 million by 2050, which will have serious personal, social and economic implications. Employing successful intervention and treatment strategi...
Authors: Shea J. Andrews, Ranmalee Eramudugolla, Jorge I. Velez, Nicolas Cherbuin, Simon Easteal and Kaarin J. Anstey
Previously, the contribution of peripheral infection to cognitive decline was largely overlooked however, the past 15 years have established a key role for infectious pathogens in the progression of age-relate...
Retinal imaging may serve as an alternative approach to monitor brain pathology in Alzheimer’s disease (AD). In this study, we investigated the association between retinal vascular and structural changes and c...
Authors: S.Mojtaba Golzan, Kathryn Goozee, Dana Georgevsky, Alberto Avolio, Pratishtha Chatterjee, Kaikai Shen, Vivek Gupta, Roger Chung, Greg Savage, Carolyn F. Orr, Ralph N. Martins and Stuart L. Graham
Despite substantial research and development investment in Alzheimer’s disease (AD), effective therapeutics remain elusive. Significant emerging evidence has linked cholesterol, β-amyloid and AD, and several s...
Authors: Nophar Geifman, Roberta Diaz Brinton, Richard E. Kennedy, Lon S. Schneider and Atul J. Butte
At present, dementia has no known cure. Interventions to delay onset and reduce prevalence of the disease are therefore focused on risk factor reduction. Previous population attributable risk estimates for wes...
Authors: Kimberly Ashby-Mitchell, Richard Burns, Jonathan Shaw and Kaarin J. Anstey
Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer’s disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may serve as a m...
Authors: Steinunn Thordardottir, Anne Kinhult Ståhlbom, Ove Almkvist, Håkan Thonberg, Maria Eriksdotter, Henrik Zetterberg, Kaj Blennow and Caroline Graff
We sought to define a cutoff for β-amyloid 1–42 in cerebrospinal fluid (CSF), a key marker for Alzheimer’s disease (AD), with data-driven Gaussian mixture modeling in a memory clinic population.
Authors: Daniela Bertens, Betty M. Tijms, Philip Scheltens, Charlotte E. Teunissen and Pieter Jelle Visser
The pathophysiology of insulin resistance-induced hypertension and hyperlipidemia might entail differences in dementia risk in cases with hypertension and hyperlipidemia without prior diabetes mellitus (DM). T...
Authors: Yen-Chun Fan, Jung-Lung Hsu, Hong-Yi Tung, Chia-Chi Chou and Chyi-Huey Bai
During adulthood, personality characteristics may contribute to the individual capacity to compensate the impact of developing cerebral Alzheimer’s disease (AD) pathology on cognitive impairment in later life....
Authors: Domilė Tautvydaitė, Deepti Kukreja, Jean-Philippe Antonietti, Hugues Henry, Armin von Gunten and Julius Popp
Carriers of the APOE ε4 allele are at increased risk of developing Alzheimer’s disease (AD), and have been shown to have reduced cerebral metabolic rate of glucose (CMRgl) in the same brain areas frequently affec...
Authors: Henrietta M. Nielsen, Kewei Chen, Wendy Lee, Yinghua Chen, Robert J. Bauer III, Eric Reiman, Richard Caselli and Guojun Bu
Amyloid precursor protein (APP) is cleaved by β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) to produce β-amyloid (Aβ), a critical pathogenic peptide in Alzheimer’s disease (AD). Aβ generation can ...
Authors: Na-Young Kim, Mi-Hyang Cho, Se-Hoon Won, Hoe-Jin Kang, Seung-Yong Yoon and Dong-Hou Kim
Noninvasive and effective biomarkers for early detection of amnestic mild cognitive impairment (aMCI) before measurable changes in behavioral performance remain scarce. Cognitive event-related potentials (ERPs...
Authors: Juan Li, Lucas S. Broster, Gregory A. Jicha, Nancy B. Munro, Frederick A. Schmitt, Erin Abner, Richard Kryscio, Charles D. Smith and Yang Jiang
Early-onset dementia patients often present with atypical clinical symptoms, hampering an accurate clinical diagnosis. The purpose of the present study was to assess the diagnostic impact of the amyloid-positr...
Authors: Marissa D. Zwan, Femke H. Bouwman, Elles Konijnenberg, Wiesje M. van der Flier, Adriaan A. Lammertsma, Frans R. J. Verhey, Pauline Aalten, Bart N. M. van Berckel and Philip Scheltens
Accumulation of hyperphosphorylated tau protein is a histopathological hallmark of Alzheimer’s disease (AD) and related tauopathies. Currently, there is no effective treatment available for these progressive n...
Authors: Chun-ling Dai, Yunn Chyn Tung, Fei Liu, Cheng-Xin Gong and Khalid Iqbal
The sortilin-related receptor 1 (SORL1) gene, regulating the trafficking and recycling of amyloid precursor protein, has been related to Alzheimer’s disease (AD) and mild cognitive impairment (MCI). The aim of th...
Authors: Cheng-Ta Chou, Yi-Chu Liao, Wei-Ju Lee, Shuu-Jiun Wang and Jong-Ling Fuh
Amyloid-β 1–42 peptide (Aβ1–42) is associated with plaque formation in the brain of patients with Alzheimer’s disease (AD). Pharmacodynamic studies of AD therapeutics that lower the concentrations of Aβ1–42 in pe...
Authors: Linan Song, D. Richard Lachno, David Hanlon, Adam Shepro, Andreas Jeromin, Dipika Gemani, Jayne A. Talbot, Margaret M. Racke, Jeffrey L. Dage and Robert A. Dean
Hyperphosphorylation and aggregation of tau protein are the pathological hallmarks of Alzheimer’s disease and related tauopathies. We previously demonstrated that the microglial activation induces tau hyperpho...
Authors: Nicole Maphis, Shanya Jiang, Guixiang Xu, Olga N. Kokiko-Cochran, Saktimayee M. Roy, Linda J. Van Eldik, D. Martin Watterson, Bruce T. Lamb and Kiran Bhaskar
Accumulating evidence implicates the neuroendocrine immunomodulation (NIM) network in the physiopathological mechanism of Alzheimer’s disease (AD). Notably, we previously revealed that the NIM network is dysre...
Authors: Jian-Hui Wang, Xi Lei, Xiao-Rui Cheng, Xiao-Rui Zhang, Gang Liu, Jun-Ping Cheng, Yi-Ran Xu, Ju Zeng, Wen-Xia Zhou and Yong-Xiang Zhang
It is unknown whether older adults in the United States would be willing to take a test predictive of future Alzheimer’s disease, or whether testing would change behavior. Using a nationally representative sam...
Authors: Meera Sheffrin, Irena Stijacic Cenzer and Michael A. Steinman
According to new diagnostic guidelines for Alzheimer’s disease (AD), biomarkers enable estimation of the individual likelihood of underlying AD pathophysiology and the associated risk of progression to AD deme...
Authors: Panagiotis Alexopoulos, Lukas Werle, Jennifer Roesler, Nathalie Thierjung, Lena Sophie Gleixner, Igor Yakushev, Nikolaos Laskaris, Stefan Wagenpfeil, Philippos Gourzis, Alexander Kurz and Robert Perneczky
Frontotemporal dementia is an increasingly studied disease, the underlying functional impairments on a neurobiological level of which have not been fully understood. Patients with the behavioral-subtype fronto...
Authors: Florian G. Metzger, Betti Schopp, Florian B. Haeussinger, Katja Dehnen, Matthis Synofzik, Andreas J. Fallgatter and Ann-Christine Ehlis
Progressive and relatively circumscribed loss of semantic knowledge, referred to as semantic dementia (SD) which falls under the broader umbrella of frontotemporal dementia, was officially identified as a clin...
Authors: Ramon Landin-Romero, Rachel Tan, John R. Hodges and Fiona Kumfor
Mild cognitive impairment (MCI) is a syndrome that disrupts an individual’s cognitive function but preserves activities of daily living. MCI is thought to be a prodromal stage of dementia, which disrupts patie...
Authors: Kyongsik Yun, In-Uk Song and Yong-An Chung
Hyperactivity of the classical axis of the renin-angiotensin system (RAS), mediated by angiotensin II (Ang II) activation of the angiotensin II type 1 receptor (AT1R), is implicated in the pathogenesis of Alzh...
Authors: Patrick Gavin Kehoe, Steffenny Wong, Noura AL Mulhim, Laura Elyse Palmer and J. Scott Miners
In a research study, to give a comprehensive evaluation of the impact of interventions, the outcome measures should reflect the lived experience of the condition. In dementia studies, this necessitates the use...
Authors: Jennifer Kirsty Harrison, Anna H. Noel-Storr, Nele Demeyere, Emma L. Reynish and Terry J. Quinn
In this study, we sought to estimate the societal cost of illness in dementia in Sweden in 2012 using different costing approaches to highlight methodological issues.
Authors: Anders Wimo, Linus Jönsson, Laura Fratiglioni, Per Olof Sandman, Anders Gustavsson, Anders Sköldunger and Lennarth Johansson
A large, prospective, 2-year, randomized study in patients with mild-to-moderate Alzheimer’s disease or mixed dementia demonstrated reductions in mortality and cognitive/functional decline in galantamine-treat...
Authors: Klaus Hager, Alan S. Baseman, Jeffrey S. Nye, H. Robert Brashear, John Han, Mary Sano, Bonnie Davis and Henry M. Richards
Current Alzheimer’s disease (AD) research initiatives focus on cognitively healthy individuals with biomarkers that are associated with the development of AD. It is unclear whether biomarker results should be ...
Authors: S. A. S. A. Bemelmans, K. Tromp, E. M. Bunnik, R. J. Milne, S. Badger, C. Brayne, M. H. Schermer and E. Richard
In this study, we examined the psychometric properties of the Affiliate Stigma Scale to measure affiliate stigma for caregivers of family members with dementia, a topic scantily covered in the literature.
Authors: Chih-Cheng Chang, Jian-An Su and Chung-Ying Lin
Results from a phase 2a study indicated that treatment with the novel α7 nicotinic acetylcholine receptor agonist ABT-126 25 mg once daily (QD) was associated with a trend for improvement in cognition in subje...
Authors: Laura M. Gault, Robert A. Lenz, Craig W. Ritchie, Andreas Meier, Ahmed A. Othman, Qi Tang, Scott Berry, Yili Pritchett and Weining Z. Robieson
There is a need to investigate biomarkers that are indicative of the progression of dementia in ethnic patient populations. The disparity of information in these populations has been the focus of many clinical...
Authors: Rinko Grewal, Mona Haghighi, Shuai Huang, Amanda G. Smith, Chuanhai Cao, Xiaoyang Lin, Daniel C. Lee, Nancy Teten, Angela M. Hill and Maj-Linda B. Selenica
Mild parkinsonian signs (MPS) are common in older people and are associated with an increased risk of different neurodegenerative diseases. This study prospectively evaluates the longitudinal course of cogniti...
Authors: Stefanie Lerche, Kathrin Brockmann, Andrea Pilotto, Isabel Wurster, Ulrike Sünkel, Markus A. Hobert, Anna-Katharina von Thaler, Claudia Schulte, Erik Stoops, Hugo Vanderstichele, Victor Herbst, Britta Brix, Gerhard W. Eschweiler, Florian G. Metzger, Walter Maetzler and Daniela Berg
Synaptic degeneration is a central pathogenic event in Alzheimer’s disease that occurs early during the course of disease and correlates with cognitive symptoms. The pre-synaptic vesicle protein synaptotagmin-...
Authors: Annika Öhrfelt, Ann Brinkmalm, Julien Dumurgier, Gunnar Brinkmalm, Oskar Hansson, Henrik Zetterberg, Elodie Bouaziz-Amar, Jacques Hugon, Claire Paquet and Kaj Blennow
The recent development of tau-specific positron emission tomography (PET) tracers has allowed in vivo quantification of regional tau deposition and offers the opportunity to monitor the progression of tau path...
Authors: Laure Saint-Aubert, Ove Almkvist, Konstantinos Chiotis, Rita Almeida, Anders Wall and Agneta Nordberg
The global impact of Alzheimer’s disease (AD) continues to increase, and focused efforts are needed to address this immense public health challenge. National leaders have set a goal to prevent or effectively t...
Authors: Jeffrey Cummings, Paul S. Aisen, Bruno DuBois, Lutz Frölich, Clifford R. Jack Jr, Roy W. Jones, John C. Morris, Joel Raskin, Sherie A. Dowsett and Philip Scheltens
Amyloid-beta (Aβ) plays a key role in Alzheimer’s disease (AD) pathogenesis, and soluble Aβ oligomers are more cytotoxic than Aβ fibrils. Recent evidence suggests that Notch signaling is affected by AD and oth...
Authors: Shuman Zhang, Pan Wang, Lili Ren, Chunli Hu and Jing Bi
The annual Alzheimer’s Research UK (ARUK) Conference was hosted by the Manchester and North West Network Centre on March 8–9, 2016. In this report, we provide a summary of the research presented.
Authors: Rosa M. Sancho, Carla J. Cox, Laura E. Phipps and Simon H. Ridley
Gamma-hydroxybutyrate (GHB or XyremR) is frequently used in humans for several clinical indications, including anesthesia, narcolepsy/cataplexy, and alcohol-withdrawal symptoms. Pharmacological effects induced in...
Authors: Michel Maitre, Christian Klein and Ayikoe G. Mensah-Nyagan
Targeting the expression of genes has emerged as a potentially viable therapeutic approach to human disease. In Alzheimer’s disease, therapies that silence the expression of tau could be a viable strategy to s...
Authors: Susan Fromholt, Christian Reitano, Hilda Brown, Jada Lewis and David R. Borchelt
Familial Alzheimer’s disease (FAD) is caused by mutations in the amyloid precursor protein (APP) or presenilin (PS). Most PS mutations, which account for the majority of FAD cases, lead to an increased ratio o...
Authors: Jean-François Blain, Matthew G. Bursavich, Emily A. Freeman, Lori A. Hrdlicka, Hilliary E. Hodgdon, Ting Chen, Don E. Costa, Bryce A. Harrison, Sudarshan Kapadnis, Deirdre A. Murphy, Scott Nolan, Zhiming Tu, Cuyue Tang, Duane A. Burnett, Holger Patzke and Gerhard Koenig
Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline...
Authors: Penny A. Dacks, Joshua J. Armstrong, Stephen K. Brannan, Aaron J. Carman, Allan M. Green, M. Sue Kirkman, Lawrence R. Krakoff, Lewis H. Kuller, Lenore J. Launer, Simon Lovestone, Elizabeth Merikle, Peter J. Neumann, Kenneth Rockwood, Diana W. Shineman, Richard G. Stefanacci, Priscilla Velentgas…
The age gap between participants in trials and patients who could benefit from the drugs studied has been widely documented across different clinical areas. Patients with dementia included in clinical research...
Authors: Rita Banzi, Paolo Camaioni, Mauro Tettamanti, Vittorio Bertele’ and Ugo Lucca
Current projections of the scale of the coming dementia epidemic assume that the age- and sex-specific prevalence of dementia will not vary over time, and that population ageing alone (increasing the number of...
Authors: Martin Prince, Gemma-Claire Ali, Maëlenn Guerchet, A. Matthew Prina, Emiliano Albanese and Yu-Tzu Wu
